MIPI Molecular Insight Pharmaceuticals(MIPI_) shares were declining Monday after rocketing by as much as 80% Friday. The troubled company -- on the verge of being delisted by Nasdaq -- said an early-stage clinical trial of a cancer diagnostic test showed positive results vs. a rival technology.
The stock finished Monday by sinking 15.8% to $1.07. Also on Friday, Molecular Insight received another waiver extension from its bondholders as it struggles to refinance its debt load.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.